menu
    • menu
    [{"orgOrder":0,"company":"Mural Oncology","sponsor":"Alkermes Plc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Nemvaleukin Alfa","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Mural Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mural Oncology \/ Alkermes Plc","highestDevelopmentStatusID":"10","companyTruncated":"Mural Oncology \/ Alkermes Plc"}]

    Find Clinical Drug Pipeline Developments & Deals by Mural Oncology

    Menu

    Mural Oncology

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Mural Oncology

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Mural Oncology

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nemvaleukin Alfa,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Alkermes Plc

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Mural Oncology Announces Enhancements to Late-Stage Clinical Trials

                            Details : Nemvaleukin is a IL-2 variant designed to harness anti-cancer capabilities of high-dose rhIL-2, currently in phase 3 clinical development for treating platinum-resistant epithelial ovarian cancer.

                            Brand Name : ALKS 4230

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            January 08, 2024

                            Lead Product(s) : Nemvaleukin Alfa,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Alkermes Plc

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth